GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (NAS:DOMH) » Definitions » Debt-to-EBITDA

Dominari Holdings (Dominari Holdings) Debt-to-EBITDA : -0.15 (As of Dec. 2023)


View and export this data going back to 1984. Start your Free Trial

What is Dominari Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dominari Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.42 Mil. Dominari Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.03 Mil. Dominari Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-22.92 Mil. Dominari Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dominari Holdings's Debt-to-EBITDA or its related term are showing as below:

DOMH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.16   Med: -0.06   Max: -0.02
Current: -0.16

During the past 13 years, the highest Debt-to-EBITDA Ratio of Dominari Holdings was -0.02. The lowest was -0.16. And the median was -0.06.

DOMH's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs DOMH: -0.16

Dominari Holdings Debt-to-EBITDA Historical Data

The historical data trend for Dominari Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Debt-to-EBITDA Chart

Dominari Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.05 -0.16

Dominari Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.24 -0.10 -0.30 -0.15

Competitive Comparison of Dominari Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, Dominari Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dominari Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Debt-to-EBITDA falls into.



Dominari Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dominari Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.421 + 3.028) / -21.354
=-0.16

Dominari Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.421 + 3.028) / -22.92
=-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Dominari Holdings  (NAS:DOMH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Dominari Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dominari Holdings (Dominari Holdings) Business Description

Traded in Other Exchanges
Address
One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Executives
Kyle Michael Wool director 650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall officer: Chief Operating Officer DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Anthony Hayes director, officer: Chief Executive Officer 1796 SHADY LANE, COLUMBIA SC 29206
George Way officer: Chief Financial Officer C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick director 10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner director ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander director 913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg director 781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner officer: Interim CFO 6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon director 6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen officer: Chief Financial Officer C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002